.2B, trading at NT$70.70 on the TWO. This SniperIQ fundamentals page covers WeLeader Biomedical's valuation (P/E 14.5x, P/B 2.8x), profitability (net margin 19.3%), revenue (NT

What is WeLeader Biomedical's P/E ratio?

WeLeader Biomedical's trailing twelve-month P/E ratio is 14.5x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is WeLeader Biomedical?

WeLeader Biomedical runs a net profit margin of 19.3%, a gross margin of 34.1%, and an operating margin of 24.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does WeLeader Biomedical generate?

WeLeader Biomedical reported revenue of NT

Does WeLeader Biomedical pay a dividend?

WeLeader Biomedical offers a trailing dividend yield of about 5.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is WeLeader Biomedical financially healthy?

WeLeader Biomedical carries a debt-to-equity ratio of 0.75x and a current ratio of 1.36x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is WeLeader Biomedical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For WeLeader Biomedical (7713) the key facts are: market cap NT

.2B, P/E 14.5x, revenue NT

Track WeLeader Biomedical's full fundamentals live

Get WeLeader Biomedical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.